Yervoy Archives -

Merck gets a leg-up for Keytruda in first-line kidney cancer

Phil Taylor Bristol-Myers Squibb, Cabometyx, Eisai, Exelixis, immuno-oncology, Inlyta, Keytruda, Lenvima, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma, Sutent, Yervoy 0 Comment

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

News/ News/ Oncology

FDA approves BMS’ Opdivo and Yervoy combination in first-line mesothelioma

Richard Staines Bristol-Myers Squibb, cancer, mesothelioma, Opdivo, Yervoy 0 Comment

Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication

FDA approves BMS’ Opdivo and Yervoy combination in first-line mesothelioma

https://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/

News/ News/ News/ Oncology/ R&D

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Phil Taylor Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, mesothelioma, Oncology, Opdivo, Yervoy 0 Comment

Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer,

BMS’ Opdivo aces trial in asbestos-linked lung cancer

https://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/

Market Access/ News/ News/ News/ Oncology

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

Phil Taylor Bristol-Myers Squibb, checkpoint inhibitors, immuno-oncology, melanoma, Oncology, Opdivo, Roche, Tecentriq, Yervoy 0 Comment

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma –

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

https://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/

News/ News/ News/ Oncology/ R&D

BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanoma

Phil Taylor Bristol-Myers Squibb, immuno-oncology, melanoma, Oncology, Opdivo, Yervoy 0 Comment

Bristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology,

BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanoma

https://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/

Market Access/ News/ News/ News/ Oncology

FDA decision on Opdivo/Yervoy in liver cancer due next March

Phil Taylor Bristol-Myers Squibb, immuno-oncology, Liver cancer, Oncology, Opdivo, Yervoy 0 Comment

The FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver

FDA decision on Opdivo/Yervoy in liver cancer due next March

https://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/

News/ News/ R&D/ Top stories

BMS pulls Opdivo/Yervoy in first-line lung cancer

Phil Taylor BMS, lung cancer, Opdivo, Yervoy 0 Comment

Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line

BMS pulls Opdivo/Yervoy in first-line lung cancer

https://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/

News/ News/ R&D

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Phil Taylor BMS, kidney cancer, Opdivo, Yervoy 0 Comment

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green

BMS gets new OK for Opdivo/Yervoy in kidney cancer

https://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/

Trending

Yervoy

Login